We investigated dopamine immunoreactivity in the s m a l l intestine of gerbils (Meriones unguiculatus), using a sensitive and selective antibody against glutaraldehyde-conjugated dopamine. Dopamine-immunoreactive cells were found within the mucosal epithelium along the entire extent of the small intestine. Labeled cells were regularly distributed in the upper half of the intestinal villi, basally attached to the basement membrane and always teaching as far as the epithelial surface. Dopamine-containing cells revealed a spindle-like shape, and both light and electron microscopic
Introduction
It is well established to date that dopamine (DA) plays a pivotal role as a true neurotransmitter in the central nervous system (CNS) (Carlson, 1987) . In contrast to earlier assumptions that outside the CNS DA occurs only as a precursor of norepinephrine (NE) and epinephrine, accumulating evidence now indicates that DA might function as a neurotransmitter in its own right in the autonomic nervous system also (Bell, 1988; Lackovic and N d , 1983; Bell, 1982; Bell and Lang, 1982) . From pharmacological studies it is assumed that DA and NE are located at separate sites (Neff et al., 1986) and DAergic neurons innervate DA receptors (Missale et al., 1986) . Both pre-and postsynaptic DA receptors could be identified in almost all tissues receiving an autonomic innervation (Lackovic and Neff, 1983) . DA modulates autonomic neuromuscular transmission (Bell and Lang, 1982) and peripheral blood ptessure (Neffet al., 1986; Goldberg et al., 1978; Karlinger, 1973; Von Essen, 1972; Goldberg, 1972; McNay et al., 1965) , and further reveals direct agonistic influences on specific DA receptors on smooth muscles and neurons (Ruffalo and Morgan, 1984) . DA also acts indirectly, causing release of NE from presynaptic terminals (Ruffalo and Morgan, 1984) .
In the gastrointestinal tract (GIT) DA is presumed also to act through specific DA receptors (Marzio et al., 1986; Valenzuela and h i , 1982; Schnurkes and Van Nueten, 1981; Lanfranchi et al., 1978) , stimulating pancreatic secretion (Hashimoto et al., 1973) , influenc- 
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ing intestinal blood flow pattern (Pawlik et al., 1976) , controlling motility of the gut (Marzio et al., 1986 (Marzio et al., ,1990 King and Gerring, 1988; Fioramonti et al., 1984; Bell and Lang, 1982; Lanfranchi et al., 1978) , and producing gastric relaxation (Van Nueten and Janssen, 1978; Valenzuela, 1976) . DA was further found to act on several smooth muscle preparations of the GIT (Grivegnee et al., 1984; Sahyoun et al., 1982; Anum, 1981; Cox and Ennis, 1980) and shows pharmacological activity on enteric neurons (Furness and Costa, 1982) . DA also functions indirectly both via release of gastrointestinal hormones, thus modulating the GIT hormone level (Di Giulio et al., 1989; Linnestad et al., 1983; Rayfield et al., 1975) , and via modulation of presynaptic release of other neurotransmitters (Kusunoki et al., 1985) .
Although DAergic neurons have not yet been directly demonstrated, from studies on DA functions it might be concluded that DAergic neurons may be present in the smooth muscle myenteric plexus throughout the entire GIT (Eaker et al., 1988) . In addition, from a long list of indications mostly gained from pharmacological investigations and microspectrofluorimetry, DA could perhaps be a constituent part of secretory products in many non-neuronal cells, such as mast cells, SIF (small intensive fluorescent) cells in sympathetic ganglia, and APUD (amine precursor uptake and decarboxylation) cells constituting the diffuse neuroendocrine system (DNES) ( N d e t al., 1986; Lacovic and Neff, 1983; Pearse, 1977 Pearse, ,1983 Heym et al., 1980; Bjorklund et al., 1970) . It has long been suspected that besides neuronal DA in the GIT, large amounts of nonneuronal DA may be present (Tjdve, 1971) . In this connection, endocrine cells of the gastroentero-pancreatic (GEP) system producing peptides and/or amines most probably synthesize and handle DA in a paracrine manner (Fujita, 1976 (Fujita, ,1989 . Nevertheless, to date a direct demonstration of DAergic entero-endocrine cells is not available.
In this study we therefore investigated DA immunoreactivity in the small intestine of gerbils (Meriones unguicufatus) using a specific antibody against glutaraldehyde-conjugated DA. Results are discussed against the background of current understanding of peripheral DA function.
Materials and Methods
Preparation of Tissue. Gerbils (Meriones unguicufutus) of both sexes were kept under natural dayhight cycles in home cages (30 x 40 cm) with two animals each. Food and water were provided ad libitum. Adult gerbils (n = 7) were transcardically perfused under deep chloral hydrate anesthesia (1.7 glkg. IP). The blood was washed out with approximately 60 ml cold oxygen-enriched 0.0s M phosphate buffer (pH 6.2) containing 1% sodium metabisulfite, followed by 500 ml 5 % glutaraldehyde with 1% sodium metabisulfite in 0.1 M phosphate buffer (pH 7.6). Finally, the fixative was quickly washed out with 0.05 M Tris-buffered saline (TBS) containing 1% sodium metabisulfite (pH 7.5; wash buffer).
Immunocytochemical Procedure. For light microscopy (Reichert-Jung, Polyvar), small intestines were subsequently kept in 30% sucrose in wash buffer overnight. Forty-pm thick cross-sections of the frozen gut were sliced on a frigocut (Reichert-Jung, Model 2700). The peroxidase-anti-peroxidase (PAP) method (Sternberger, 1979) was the chosen immunocytochemical procedure, which was performed free-floating using the following incubations: (a) pre-incubation in 0.5% H202 (10 min, 4'C) to eliminate endogeneous peroxidase activity: (b) pre-incubation in 10% normal goat serum (NGS; Sigma, Deisenhofen, FRG) in wash buffer (0.S hr, 4°C) to reduce nonspecific background staining; (c) rabbit antiserum against glutaraldehydeconjugated dopamine (DA) (Incstar: Stillwater, MN) diluted 1:lOOO in wash buffer containing 0.4% Triton X-100 and 1% NGS (16 hr, 4°C) to improve antibody penetration. This highly specific and sensitive antibody against DA was first obtained and characterized by Geffard et al. (1984) . Specificity controls included radioimmunological assays and incubations with catecholamine-covered Sepharose beads to exclude cross-reaction (Buijs et al., 1984) ; (d) three 10-min washes in wash buffer; (e) goat anti-rabbit serum (GAR Sigma) diluted 1:50 in TBS containing 0.4% Triton x-100 and 1% NGS (2 hr, room temperature); (f) three 10-min washes; (9) peroxidase-anti-peroxidase (PAP; Sigma) in the same dilution buffer as for GAR, 1:500 (2 hr, room temperature); (h) three 10-min washes; (i) 0.05°/o 3,3'diaminobenzidine (DAB: Sigma) and 0.01% H202 in TBS containing 2 % (NH4)2S04NiS04 (15 min, room temperature); (j) three 10-min washes;
(k) sections were dried on glass slides overnight, dehydrated, mounted in DePeX (Serva; Heidelberg, FRG), and coverslipped.
Control sections were treated as described above, but the primary antibody was omitted or pre-treated with DA conjugated to bovine serum albumin with glutaraldehyde, the same antigen used to generate the antibody. No immunolabeled cells were seen in either case. Although the antibody serum used reveals some nonspecific affinity to connective tissues, nevertheless specific locations were easily identified in epithelial cells using the above-described procedure.
Preparation for Electron Microscopy. The immunostaining procedure described above was particularly adapted for electron microscopy. Immediately after perfusion, small intestines were dissected and 80-pm thick crosssections performed with a vibratome (Model G; Campden Instruments, London, UK), which were collected in wash buffer at 4'C. No Triton X-100 was added to the sera used. Antiserum against glutaraldehyde-conjugated DA was applied over 42 hr at 4'C (c), and both GAR and PAP were added for 2 hr at 37°C (e,g). DAB was applied without (NH4)2S04NiS04 (i). After three 10-min washes (j) sections were incubated in 2% Os04 for 1 hr. Slices were finally washed. dehydrated and flat-embedded in Epon (Serva). Semithin sections (1 pm) were provided in order to detect immunolabeled cells by phase-contrast microscopy (Zeiss) before ultra-thin sections for electron microscopic analysis (Hitachi).
Results
DA immunoreactivity was found in cells of the mucosal epithelium regularly distributed throughout the small intestine. These cells, which originate in the crypt, obviously start to form DA only when they have moved at least about half-way towards the tip of the villi, where they could frequently be seen in a state of exfoliation (Figure la) . The labeled cells revealed a typical spindle-like shape, with DA immunoreactivity concentrated at their basal pole ( Figures Ib and IC) , and always appeared to be attached to the basement membrane, reaching the gut lumen by their conical apical tip ( Figures Ib-Id) . The central cell of the three labeled cells, located between neighboring cylindrical absorptive cells ( Figure Id) , is presented in the electron micrographs of Figure 2 . In noncontrasted ultra-thin slices, electron-dense precipitates resulting from selective PAP complexes could be detected (Figure 2a ) and were easily recovered in subsequent slices contrasted with uranyl acetate and lead citrate (Figure 2b ). Large DA-immunoreactive electron-dense granules are visible above the nucleus and concentrated at the basal pole of the cell.
Discussion
The present study has demonstrated dopamine immunoreactivity in basal granulated cells of the mucosal epithelium of the small intestine in gerbils. These cells resemble typical open-type gut endocrine cells (Fujita and Kobayashi, 1973) as part of the gastrointestinal endocrine system (Vigna, 1986; Fujita, 1976) . After DA had been suspected to be handled by gastroenteric endocrine cells (Fujita, 1976; Tjalve, 1971) , this current study directly identified DA in cells of this type.
The DAergic cells detected in the gut share light and electron microscopic characteristics with recepto-secretory endocrine cells which have been described as paraneurons (Fujita, 1989; Kanno, 1989; Fujita et al., 1980) . Corresponding with the APUD cell concept (Pearse, 1983 (Pearse, ,1986 , paraneurons are assumed to produce both peptides and amines. Therefore, DA has also been presumed to coexist with various bioactive peptides in non-neuronal peripheral cells [e.g., with Met-enkephalin in Type 1 cells of the carotid body, with pancreatic polypeptide and somatostatin in D-and PP-cells of the pancreas, and with calcitonin in parafollicular cells (Pearse, 1983; Fujita, 1976) ]. Therefore, in the intestine several of the wellknown peptides secreted by GEP-cells, e.g., somatostatin, gastrin, cholecystokinin (CCK), gastric inhibitory peptide (GIP), neurotensin, secretin, motilin, and vasoactive intestinal peptide (VIP) are probable candidates to coexist with DA (Vigna, 1986; Pearse, 1983) . It would be of particular interest to analyze how many and which peptides, if any, may be co-released with DA from entero-endocrine cells, and to further study their mutual role in modulating the GIT hormone level. Nevertheless, from histological features of DAergic basal granulated cells, DA most likely is involved in transducing signals from inside the bowel into adaptive response patterns of the GIT. Unless DA is not directly shown to exist in enteric nerve terminals, these DAergic entero-endocrine cells may be the major source of gastrointestinal DA. Since this study investigated solely the small intestine, it cannot be excluded thus far that DAergic endocrine cells are found in other regions of the GIT.
Various peptides and amines are equally released from gastroenteric neuronal as well as non-neuronal sites (Taylor and Bywater, 1989; Vigna, 1986) . Although pharmacological studies indicate a transmitter-like release of DA in the GIT. it remains particularly difficult to distinguish between transmitter release and hormone release (Taylor and Bywater, 1989) . In paraganglionic cells of sympathetic ganglia, both functions may appear as a dual mechanism, with assumed DAergic SIF-cells acting both as interneurons and endocrine cells (Heym et al., 1980) , mutually influencing blood pressure via modulation of ganglionic transmission (Neff et al., 1986) .
Although pharmacological, histological, and physiological data on the gastrointestinal endocrine system are accumulating (Cetin, 1990a,b; Yui et al., 1990; Taylor and Bywater, 1989) , we are only just beginning to understand the complex interplay among the many bioactive peptides and amines that coordinate basic functions of the GIT in an astonishingly adaptive manner. In this connection, DA, as well as other amines, is well known to act via modulation of neuronal and non-neuronal release, regulating various hormone-and transmitter-like functions in the GIT (Di Giulio et al.. 1989; Kusunoki et al., 1985; Linnestad et al., 1983; Hashimoto et al., 1973) . Another important action of biogenic amines seems to be regulation of the proliferative activity of undifferentiated crypt cells by sympathetic neurons as well as entero-endocrine cells (Holle et al., 1989; Tutton and Barkla, 1987) . There is some indication that besides NA and 5HT. DA might also be involved in this kind of structural adaptation (Tutton and Barkla, 1987) .
In the light of the significance of these various functions, it can be discussed whether DA serves as a hormone or as a parahormone. Mindful of the fact that bioactive substances could function in either way, low plasma concentrations of DA seem to speak against it as a circulating hormone (Lackovic and Neff, 1983) . Therefore, DA in the GIT is more likely to act in a paracrine manner, which is in good agreement with the regular and diffuse distribution pat- Original magnification x 10,000. Bars = 1 pm.
tern of DA-immunoreactive cells throughout the mucosal epithelium of the entire small intestine. Furthermore, locally acting DA. rather than being distributed by blood capillaries or lymphatic vessels, would be a subtle tool to orchestrate spatially specific functional and structural response patterns along the digestive tract.
In conclusion, since DA-containing cells can now easily be detected in the GIT, several questions may be posed: (a) Which peptides coexist with DA in entero-endocrine cells? (b) What are the neuronal andlor non-neuronal targets for DA released from these cells? (c) Does "DA-containing" equally mean "DA-producing"? 
